Baseline circulating soluble factors as predictors of immune-related adverse events (irAEs) in patients (pts) with metastatic clear cell renal carcinoma (mRCC) treated with nivolumab: A translational NIVOREN GETUG-AFU 26 study.

被引：0
|
作者：
Carril-Ajuria, Lucia
Naigeon, Marie
Dalban, Cecile
Desnoyer, Aude
Rioux-Leclercq, Nathalie
Sautes-Fridman, Catherine
Meylan, Maxime
Vano, Yann-Alexandre
Beusenlick, Benoit
Chouaib, Salem
de Oliveira, Caroline
Tantot, Florence
Flippot, Ronan
Escudier, Bernard
Albiges, Laurence
Chaput, Nathalie
机构：
[1] Inst Gustave Roussy, Med Oncol, Villejuif, France
[2] Gustave Roussy, Lab Immunomonitoring Oncol, Villejuif, France
[3] Ctr Leon Berard, Lyon, France
[4] AP HP, Paris, France
[5] Pontchaillou Univ Hosp Ctr, Rennes, France
[6] Sorbonne Univ, Univ Paris Cite, INSERM, Ctr Rech Cordeliers, Paris, France
[7] Univ Paris Cite, Dept Med Oncol, Hop Europeen Georges Pompidou, AP HP Ctr,Inst Canc Paris CARPEM,, Paris, France
[8] Univ Hosp Leuven, Gen Med Oncol, B-3000 Leuven, Belgium
[9] Gustave Roussy Canc Campus, Villejuif, France
[10] Gustave Roussy, Lab Immunooncol, F-94800 Villejuif, France
[11] UNICANCER, Le Kremlin Bicetre, France
[12] Gustave Roussy, Villejuif, MA, France
[13] Univ Paris Sud, Dept Canc Med, Gustave Roussy Canc Campus, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
724
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Association of adrenal metastases with outcomes in patients with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab in the GETUG-AFU-26 NIVOREN phase II trial.
    Billon, Emilien
    Dalban, Cecile
    Oudard, Stephane
    Chevreau, Christine
    Laguerre, Brigitte
    Barthelemy, Philippe
    Borchiellini, Delphine
    Geoffrois, Lionnel
    Negrier, Sylvie
    Joly, Florence
    Thiery-Vuillemin, Antoine
    Gross-Goupil, Marine
    Rolland, Frederic
    Priou, Frank
    Mahammedi, Hakim
    Tantot, Florence
    Escudier, Bernard
    Chabaud, Sylvie
    Albiges, Laurence
    Gravis, Gwenaelle
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [22] Association of statins and nivolumab activity in patients with metastatic renal cell carcinoma (mRCC): Results from the phase II nivoren-GETUG AFU 26 trial.
    Colomba, Emeline
    Flippot, Ronan
    Dalban, Cecile
    Negrier, Sylvie
    Chevreau, Christine
    Gravis, Gwenaelle
    Oudard, Stephane
    Laguerre, Brigitte
    Barthelemy, Philippe
    Goupil, Marine Gross
    Geoffrois, Lionnel
    Rolland, Frederic
    Thiery-Vuillemin, Antoine
    Joly, Florence
    Ladoire, Sylvain
    Tantot, Florence
    Escudier, Bernard
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [23] Is body mass index (BMI) associated with favorable outcomes in metastatic renal cell carcinoma (mRCC) treated with nivolumab? An ancillary study of the NIVOREN-GETUG AFU-26 trial
    Colomba, Emeline
    Dalban, Cecile
    Flechon, Aude
    Chevreau, Christine
    Gravis, Gwenaelle
    Thibault, Constance
    Laguerre, Brigitte
    Barthelemy, Philippe
    Borchiellini, Delphine
    Goupil, Marine Gross
    Geoffrois, Lionnel
    Rolland, Frederic
    Thiery-Vuillemin, Antoine
    Joly, Florence
    Ladoire, Sylvain
    Tantot, Florence
    Escudier, Bernard
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [24] Efficacy and safety of nivolumab in renal cell carcinoma patients with BONE metastases: Results of the GETUG: AFU 26 nivoren multicenter phase II study.
    Velev, Maud
    Dalban, Cecile
    Chevreau, Christine
    Gravis, Gwenaelle
    Negrier, Sylvie
    Laguerre, Brigitte
    Gross-Goupil, Marine
    Ladoire, Sylvain
    Ferrari, Victoria
    Geoffrois, Lionnel
    Curcio, Hubert
    Priou, Frank
    Thomas, Quentin Dominique
    Mione, Cecile
    Barthelemy, Philippe
    Tantot, Florence
    Escudier, Bernard
    Chabaud, Sylvie
    Albiges, Laurence
    Thibault, Constance
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [25] Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab
    Ishihara, Hiroki
    Takagi, Toshio
    Kondo, Tsunenori
    Homma, Chie
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Iizuka, Junpei
    Kobayashi, Hirohito
    Okumi, Masayoshi
    Ishida, Hideki
    Tanabe, Kazunari
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (06) : 355.e21 - 355.e29
  • [26] Safety and efficacy of restarting immune checkpoint inhibitors (CPI) after immune-related adverse events (irAEs) in metastatic renal cell carcinoma (mRCC).
    Abou Alaiwi, Sarah
    Martini, Dylan J.
    Xie, Wanling
    Nassar, Amin
    Bakouny, Ziad
    Steinharter, John A.
    Nuzzo, Pier Vitale
    Flippot, Ronan
    Chanza, Nieves M.
    Wei, Xiao X.
    McGregor, Bradley Alexander
    Bilen, Mehmet Asim
    Choueiri, Toni K.
    Harshman, Lauren Christine
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [27] The predictive biomarker for immune-related adverse events (irAEs) in patients with metastatic renal cell carcinoma treated with the combination therapy of nivolumab plus ipilimumab: Musashino study-irAE
    Kizawa, R.
    Kuno, M.
    Washino, S.
    Shirotake, S.
    Izumi, K.
    Inoue, M.
    Kagawa, M.
    Takeshita, H.
    Hyodo, Y.
    Kawakami, S.
    Saito, K.
    Kageyama, Y.
    Oyama, M.
    Miyagawa, T.
    Miura, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S1488 - S1488
  • [28] Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
    Ikeda, Takashi
    Ishihara, Hiroki
    Nemoto, Yuki
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Takagi, Toshio
    Iizuka, Junpei
    Hashimoto, Yasunobu
    Ishida, Hideki
    Kondo, Tsunenori
    Tanabe, Kazunari
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (10) : 735.e9 - 735.e16
  • [29] Correlation between immune-related adverse events and prognosis in renal cell carcinoma patients treated with nivolumab
    Kato, Taigo
    Nagahara, Akira
    Kawamura, Norihiko
    Nakata, Wataru
    Soda, Tetsuji
    Matsuzaki, Kyosuke
    Hatano, Koji
    Kawashima, Atsunari
    Ujike, Takeshi
    Imamura, Ryoichi
    Nishimura, Kensaku
    Takada, Shingo
    Tsujihata, Masao
    Yamaguchi, Seiji
    Takao, Tetsuya
    Nishimura, Kazuo
    Uemura, Motohide
    Nonomura, Norio
    ANNALS OF ONCOLOGY, 2021, 32 : S314 - S314
  • [30] Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
    Hayase, T.
    Washino, S.
    Shirotake, S.
    Inoue, M.
    Kagawa, M.
    Takeshita, H.
    Miura, Y.
    Hyodo, Y.
    Izumi, K.
    Kawakami, S.
    Saito, K.
    Kageyama, Y.
    Oyama, M.
    Miyagawa, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S1488 - S1489
12345